Population Pharmacokinetics and Pharmacodynamics of Depemokimab in People with Asthma and Chronic Rhinosinusitis with Nasal Polyps
The Journal of Clinical Pharmacology · 2026
DOI: 10.1002/jcph.70187 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift The Journal of Clinical Pharmacology, 2026. Verfasst von Anders Thorsted und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Modelling and Simulation, GSK, Solna, Sweden. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Asthma, Nasal Polyps, Rhinosinusitis. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK, GlaxoSmithKline.
Abstract (Originalsprache)
Depemokimab is the first ultra‐long‐acting biologic with enhanced interleukin‐5 (IL‐5) binding affinity, high potency, and extended half‐life, enabling twice‐yearly dosing. Depemokimab has demonstrated efficacy and safety in patients with asthma and chronic rhinosinusitis with nasal polyps. These analyses aimed to characterize the pharmacokinetic/pharmacodynamic (PK/PD) profile of depemokimab. Data from three Phase I studies (NCT03287310/NCT05140200/NCT05602025) and four Phase III studies (SWIFT‐1/‐2: NCT04719832/NCT04718103; ANCHOR‐1/‐2: NCT05274750/NCT05281523) were used to develop a PK model for depemokimab and PK/PD model for blood eosinophil count (BEC) reduction, a key biomarker of type 2 inflammation. Participants received subcutaneous depemokimab or placebo (one dose in Phase I [2‐300 mg in NCT03287310; 100 mg or 300 mg in NCT05140200/NCT05602025] and two 100 mg doses in Phase III) and ≥1 post‐first‐dose PK/PD (BEC) observation. PK analysis included 961 participants and PK/PD analysis included 1324 participants. Predicted geometric mean half‐life was 47 days, with negligible accumulation in PK. Depemokimab 100 mg rapidly reduced BEC to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology Modelling and Simulation, GSK, Solna, Sweden.
- Pharmetheus AB, Uppsala, Sweden.
- Clinical Research, Respiratory, Inflammation and Immunology Research Unit (RIIRU), GSK, London, UK.
- Biostatistics, GSK, London, UK.
- Upper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, Belgium.
- Oxford Respiratory NIHR Biomedical Research Centre, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
ORCID-Profile: Anders Thorsted, Nicholas Bird, Philippe Gevaert
Förderung
- GSK
- GlaxoSmithKline
Zitieren
APA
Thorsted, A., Tanneau, L., Lavalley-Morelle, A., Follows, R., Jacques, L., Bird, N., Gevaert, P., Pavord, I., Ribbing, J., Gupta, A., Howarth, P., & Schalkwijk, S. (2026). Population Pharmacokinetics and Pharmacodynamics of Depemokimab in People with Asthma and Chronic Rhinosinusitis with Nasal Polyps. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70187
Vancouver
Thorsted A, Tanneau L, Lavalley-Morelle A, Follows R, Jacques L, Bird N, et al. Population Pharmacokinetics and Pharmacodynamics of Depemokimab in People with Asthma and Chronic Rhinosinusitis with Nasal Polyps. The Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70187
BibTeX
@article{Thorsted2026,
author = {Thorsted, Anders and Tanneau, Lénaïg and Lavalley-Morelle, Alexandra and Follows, Richard and Jacques, Loretta and Bird, Nicholas and Gevaert, Philippe and Pavord, Ian and Ribbing, Jakob and Gupta, Anubha and Howarth, Peter and Schalkwijk, Stein},
title = {Population Pharmacokinetics and Pharmacodynamics of Depemokimab in People with Asthma and Chronic Rhinosinusitis with Nasal Polyps},
journal = {The Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/jcph.70187}
}
EUVIMED